|

A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

RECRUITINGPhase 3Sponsored by Yizhuo Zhang
Actively Recruiting
PhasePhase 3
SponsorYizhuo Zhang
Started2017-01-30
Est. completion2029-09
Eligibility
Age0 Years – 18 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06836492

Summary

The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

Eligibility

Age: 0 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

1. 0 years \< age \< 18 years old, regardless of gender;
2. Tumor patients diagnosed by histopathology or bone marrow cytology;
3. Patients are treated for the first time;
4. ECoG score ≤ 2;
5. The expected survival time is more than 8 months;
6. Patient's parent or guardian signs informed consent.

Exclusion Criteria:

1. Combined with immunodeficiency disease
2. Second tumor

Conditions3

CancerPediatric CancerRhabdomyosarcoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.